 CAMBRIDGE, Mass., May 04, 2022 GLOBE NEWSWIRE -- Beam Therapeutics Inc. Nasdaq: BEAM, a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in fireside chats during the following May investor conferences: 